Hepatic dosing for psychiatric medications
Which psychiatric meds are LFT-friendly, which need dose reduction by Child-Pugh class, and which to avoid outright in liver disease.
Child-Pugh class primer
Child-Pugh scoring is how most package inserts describe hepatic adjustments, and it's worth remembering the components rather than just the letter grade. Five variables, each scored 1 to 3 points.
| Variable | 1 point | 2 points | 3 points |
|---|---|---|---|
| Total bilirubin | Below 2 mg/dL | 2 to 3 mg/dL | Above 3 mg/dL |
| Serum albumin | Above 3.5 g/dL | 2.8 to 3.5 g/dL | Below 2.8 g/dL |
| INR | Below 1.7 | 1.7 to 2.3 | Above 2.3 |
| Ascites | None | Mild, diuretic-responsive | Moderate to severe |
| Hepatic encephalopathy | None | Grade 1 to 2 | Grade 3 to 4 |
Add them up. Class A is 5 to 6 points (compensated cirrhosis). Class B is 7 to 9 points (significant decompensation). Class C is 10 to 15 points (advanced decompensation). The practical takeaway: mild transaminase elevations without synthetic dysfunction (normal bilirubin, albumin, INR) aren't Child-Pugh A. They're just a hepatologist referral.
The glucuronidation shortcut
If you remember one hepatic pearl, remember this: lorazepam, oxazepam, and temazepam ("LOT") are conjugated via phase II glucuronidation, which is preserved even in advanced cirrhosis. Everything else in the benzo class goes through phase I (CYP450) metabolism, which drops sharply in Child-Pugh B and C.
Practically, that means:
- Lorazepam (Ativan) is the workhorse in liver disease. Half-life doesn't change much even in cirrhosis. Reliable dosing.
- Oxazepam (Serax) and temazepam (Restoril) are similar. Less common in current practice but pharmacologically clean.
- Diazepam, chlordiazepoxide, clonazepam, alprazolam, midazolam all rely on CYP3A4 and can accumulate to dangerous levels in cirrhosis. Diazepam is the worst; half-life can extend past 100 hours.
The LOT rule doesn't mean benzos are safe in liver disease. Cirrhotic patients are more sensitive to sedation, they're at higher baseline risk for hepatic encephalopathy, and any benzo can precipitate that. It just means that if you're going to use one, the glucuronidated ones are the least bad choice.
The main hepatic-adjusted psychiatric drugs
| Drug | Metabolism | Child-Pugh A | Child-Pugh B | Child-Pugh C | Notes |
|---|---|---|---|---|---|
| Valproate | CYP, glucuronidation, hepatic | Avoid | Avoid | Contraindicated | Boxed hepatotoxicity warning. Watch for idiosyncratic fatal hepatitis, especially under age 2 and with polytherapy |
| Duloxetine | CYP1A2, 2D6 | Use caution | Avoid | Avoid | Package insert says don't use in chronic liver disease or heavy alcohol use |
| Nefazodone | CYP3A4 | Avoid | Avoid | Contraindicated | Boxed warning for fatal hepatic failure. Rarely appropriate in modern practice |
| Atomoxetine | CYP2D6 | Standard dose | Reduce to 50% | Reduce to 25% | Boxed warning for severe liver injury; discontinue with jaundice or elevated bilirubin |
| Naltrexone | Hepatic | Standard dose | Use caution | Avoid | Contraindicated in acute hepatitis or hepatic failure. LFT monitoring |
| Disulfiram | Hepatic | Use caution | Avoid | Contraindicated | Rare fulminant hepatitis; check LFTs at baseline, 2 weeks, then periodically |
| Sertraline | CYP2C19, 2D6 | Standard dose | Reduce dose, longer intervals | Avoid or nephrology-level caution | Usually the first-line SSRI in mild to moderate hepatic disease |
| Fluoxetine | CYP2D6, 2C9 | Standard dose | Reduce dose, extend interval | Reduce further | Long half-life makes dose adjustment slow and hard to reverse |
| Citalopram | CYP2C19, 3A4 | Max 20 mg | Max 20 mg | Avoid or use lowest dose | QT prolongation risk plus reduced clearance |
| Escitalopram | CYP2C19, 3A4 | Standard dose | Max 10 mg | Max 10 mg | Cleaner than citalopram at higher doses |
| Paroxetine | CYP2D6 | Reduce starting dose | Reduce further | Avoid | Anticholinergic and discontinuation issues are separate concerns |
| Bupropion | CYP2B6 | Reduce dose or frequency | Max 75 mg daily | Avoid | Seizure threshold matters more with accumulation |
| Mirtazapine | CYP1A2, 2D6, 3A4 | Standard dose | Reduce ~30% | Reduce further | Generally well tolerated |
| Venlafaxine | CYP2D6 | Reduce 50% | Reduce 50% | Reduce further | BP monitoring regardless |
| Desvenlafaxine | Direct conjugation | Standard dose | Max 100 mg | Max 100 mg | Doesn't need heavy CYP handling, which helps |
| TCAs (nortriptyline, amitriptyline, imipramine) | CYP2D6, others | Reduce 25 to 50% | Reduce 50% | Avoid | Anticholinergic and QT concerns compound the metabolism issue |
| MAOIs (phenelzine, tranylcypromine) | Hepatic | Reduce dose | Avoid | Avoid | Rarely used, hepatotoxicity signal with phenelzine |
| Lamotrigine | Glucuronidation | Reduce 25% | Reduce 50% | Reduce 75% | Rash risk is separate; go slow regardless |
| Carbamazepine | CYP3A4 (autoinducer) | Use caution | Avoid | Contraindicated | Hepatotoxicity signal plus complex interactions |
| Oxcarbazepine | Hepatic | Standard dose | Reduce | Avoid | Better hepatic profile than carbamazepine |
| Quetiapine | CYP3A4 | Reduce starting dose | Reduce further | Reduce further | Sedation compounds hepatic encephalopathy risk |
| Aripiprazole | CYP2D6, 3A4 | Usually no adjustment | Usually no adjustment | Consider lower dose | Unusually forgiving in liver disease |
| Olanzapine | CYP1A2 | Usually no adjustment | Reduce starting dose | Use caution | Metabolic side effects are the bigger concern anyway |
| Clozapine | CYP1A2, 3A4 | Reduce starting dose | Reduce further | Avoid | Agranulocytosis and other monitoring already high; hepatotoxicity signal exists |
| Lithium | Renal, not hepatic | Standard dose | Standard dose | Standard dose | Watch fluid shifts, ascites diuretics, and dehydration |
The drugs to actively avoid
Valproate. The boxed warning is real. Idiosyncratic fatal hepatic failure occurs most often in the first 6 months, more common in children under 2 and in patients with mitochondrial disease. Even in adults without those risk factors, valproate isn't the first pick if there's any suggestion of underlying liver disease. Ammonia elevation without transaminitis is a separate issue and can cause encephalopathy at normal LFTs.
Nefazodone. Rate of hepatic failure is roughly 1 in 250,000 to 1 in 300,000 patient-years, but it's specifically severe (transplant or death). It's rarely worth using in modern practice given the alternatives. If a patient is stable on it and has been for years with normal LFTs, that's a different conversation, but starting it is hard to justify.
Duloxetine. The label warns against use in chronic liver disease or substantial alcohol use. Post-marketing hepatotoxicity reports include hepatitis and jaundice. If you have a patient who drinks daily and needs an SNRI, venlafaxine is a cleaner option (still with dose reduction) than duloxetine.
Disulfiram in active liver disease. Rare but well-documented fulminant hepatitis. If you're using disulfiram, baseline LFTs and follow-up at 2 weeks and periodically thereafter aren't optional.
Sertraline as the default SSRI in liver disease
Sertraline is the first-line SSRI in mild to moderate hepatic impairment for a few reasons. Half-life extends about 3-fold in Child-Pugh A cirrhosis, which is manageable with a lower starting dose (25 mg) and slower titration. It has fewer significant CYP interactions than fluoxetine or paroxetine. It's the SSRI with the most data in liver transplant patients.
Fluoxetine works, but the long half-life becomes a liability if the patient develops an adverse effect and you need to wash it out. Escitalopram is fine at low doses. Paroxetine's anticholinergic profile and discontinuation syndrome make it a poor pick regardless of liver function.
What to do about mild LFT bumps
New antidepressants, mood stabilizers, and antipsychotics all cause transient transaminase elevations at rates that vary by drug but are almost never clinically significant on their own. A few practical rules:
- Less than 3x upper limit of normal (ULN), asymptomatic, normal bilirubin and INR: monitor, don't stop. Recheck in 2 to 4 weeks.
- 3 to 5x ULN, asymptomatic, normal synthetic function: recheck sooner (1 week), consider reducing dose, look for other causes (alcohol, other new meds, viral illness).
- Above 5x ULN, or any symptomatic (jaundice, RUQ pain, malaise), or synthetic dysfunction: stop the drug and work up.
- Bilirubin elevation with transaminitis (Hy's law): stop and refer to hepatology. This predicts serious injury.
Valproate is the exception to the "don't panic over mild bumps" rule. Any hepatic sign or symptom in a patient on valproate, especially early in therapy, deserves prompt attention.
Lithium in liver disease
Lithium is renally cleared, so hepatic function doesn't change its handling directly. What does matter:
- Ascites and diuretics. Cirrhotic patients on furosemide or spironolactone have unpredictable volume states, and lithium levels can swing.
- Alcohol use. Continued heavy drinking makes lithium adherence and hydration erratic. That's the bigger issue than metabolism.
- Encephalopathy. Lithium toxicity mimics hepatic encephalopathy (tremor, confusion, myoclonus). If a cirrhotic patient on lithium develops new confusion, check a level before assuming it's hepatic.
Common questions
Which benzo do I pick for a cirrhotic patient?
Lorazepam is the standard answer. It's glucuronidated (phase II), so its handling is preserved even in Child-Pugh B and C. Oxazepam and temazepam work by the same mechanism. Diazepam, chlordiazepoxide, alprazolam, clonazepam, and midazolam all rely on phase I metabolism (CYP450) and can accumulate dangerously. If a patient with cirrhosis needs alcohol withdrawal management, lorazepam-based protocols are safer than chlordiazepoxide-based ones despite chlordiazepoxide being the traditional choice.
Are SSRIs really fine in mild cirrhosis?
Mostly, yes. Sertraline at 25 to 50 mg starting dose is well tolerated in Child-Pugh A. Escitalopram is fine at 5 to 10 mg. Fluoxetine works but is harder to reverse if you don't like the response. Watch for GI bleeding risk in patients with varices; SSRIs modestly increase bleeding risk, and that matters more in cirrhosis. Serotonin syndrome risk is the same as in healthy patients.
How do I dose duloxetine in a heavy drinker?
Don't. The label specifically warns against use in patients with substantial alcohol use because of the hepatotoxicity signal. If a patient meets criteria for AUD and needs an SNRI, venlafaxine is the alternative (with dose reduction based on liver function), or you can switch classes entirely. Bupropion is another option if seizure risk is acceptable. Managing the alcohol use is a bigger lever than the antidepressant choice.
When does an ALT bump on valproate mean stop?
Isolated ALT under 3x ULN in an asymptomatic patient in the first 3 months of valproate is common and usually settles. Above 3x ULN, or any elevation with symptoms (nausea, malaise, jaundice, RUQ pain), or bilirubin elevation, or coagulopathy, means stop and work up. Ammonia can rise independently of LFTs on valproate and cause encephalopathy at normal transaminases, so a confused patient on valproate deserves an ammonia check even if the ALT is fine.
Is nefazodone ever appropriate anymore?
Rarely. It's still on the market and has some genuine advantages (5-HT2A antagonism helps sleep, low sexual dysfunction), but the hepatic failure signal is severe enough that most clinicians won't start it. A patient who has been stable on it for years without LFT changes is a reasonable exception. Starting it fresh in someone else, given the alternatives (mirtazapine, trazodone-augmented SSRI), is hard to defend.
Sources
- FDA labels via DailyMed for all listed medications.
- AASLD Practice Guidance on drug-induced liver injury (2019, updated 2023).
- AASLD Practice Guidance on the management of alcohol use disorder in patients with cirrhosis.
- Stahl's Essential Psychopharmacology, 5th edition.
- Package inserts for nefazodone, duloxetine, atomoxetine, valproate.
- LiverTox database (NIH) for hepatotoxicity ranking of psychiatric medications.
Reviewed against current guidelines as of June 8, 2026. This is not medical advice.
THE KNOWLEDGE PATH
Walk this topic outward.
- GUIDE Hepatic dosing for psychiatric medications (current)
- CLASS SSRIs
- MEDICATION Sertraline (Zoloft)
- CONDITION Major Depressive Disorder (on Shrinkopedia)
- CARE Depression care at shrinkMD
The Knowledge Path is a curated walk. Every step is one decision away from the next.
Managing a medication needs a prescriber
Any psychiatric medication has to be started and adjusted by a clinician who can follow you over time. If you don't have a prescriber, our guides section explains the options, including in-person care and telepsychiatry, and how to choose between them.